Summary
Pacibekitug, an antibody targeting interleukin-6, hit the primary endpoint in the phase 2 Tranquility trial by sharply reducing levels of C-reactive protein (CRP), a biomarker for cardiovascular disease risk, in patients with chronic kidney disease, Tourmaline reported May 20.
Source: Fierce Biotech
Exclusive AI-Powered News Insights (For Members only)
Disclaimer:This content is AI-generated from various trusted sources and is intended for informational purposes only. While we strive for accuracy, we encourage you to verify details independently. Use the contact button to share feedback on any inaccuracies—your input helps us improve!
